<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233892</url>
  </required_header>
  <id_info>
    <org_study_id>SC201900202</org_study_id>
    <nct_id>NCT04233892</nct_id>
  </id_info>
  <brief_title>Clinical Study of in Situ Regeneration of Endometrium</brief_title>
  <official_title>Clinical Study of in Situ Regeneration of Endometrium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yali Hu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thin endometrium will lead to hypomenorrhea，infertility and recurrent pregnancy loss and
      there are few effective methods to increase the endometrial thickness and improve the
      fertility outcomes. Patients with thin endometrium will be divided into three groups and
      receive estrogen therapy, stem cell therapy and growth factor therapy respectively. This
      randomized controlled clinical study is carried out to explore the optimal treatment method
      and best indications for thin endometrium.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>6 months</time_frame>
    <description>Endometrial thickness evaluated by transvaginal sonography during late proliferative phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>24 months</time_frame>
    <description>The presence of a living intrauterine fetus on TVU at the 12th week of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endometrial blood flow</measure>
    <time_frame>6 months</time_frame>
    <description>Endometrial blood flow evaluated by transvaginal sonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy related complications</measure>
    <time_frame>24 months</time_frame>
    <description>Miscarriage rate, live birth rate, ET cycle cancellation rate,Placenta related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological changes of endometrium</measure>
    <time_frame>12 months</time_frame>
    <description>Histological changes of the thin endometrium before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual blood volume</measure>
    <time_frame>6 months</time_frame>
    <description>The change of menstrual blood volume after treatment compared with pre-treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>24 months</time_frame>
    <description>The occurrence of infections, allergies, abdominal pain, uterine perforation and etc.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">345</enrollment>
  <condition>Infertility, Female, of Uterine Origin</condition>
  <condition>Endometrial Fibrosis</condition>
  <arm_group>
    <arm_group_label>CBD-bFGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Collagen/BMMNCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD-bFGF</intervention_name>
    <description>CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound</description>
    <arm_group_label>CBD-bFGF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Collagen/BMMNCs</intervention_name>
    <description>A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound</description>
    <arm_group_label>Collagen/BMMNCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogen</intervention_name>
    <description>Patients will receive regular estrogen therapy</description>
    <arm_group_label>Estrogen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Patients with thin endometrium (4mm≤ EMT ＜7mm )or scarred endometrium (scarred area≤70%)
        which is nonresponsive to estrogen stimulation 2.Infertile patients with clear fertility
        desires 3.20-42 years old 4.Normal ovarian function or with frozen embryos 5.Willing to
        participate in follow-up

        Exclusion Criteria:

          1. Endometrial thickness ＜4mm or scarred endometrial area＞70%

          2. Uterine cavity out of shape and the cavity depth＜6.5mm

          3. Abnormal chromosome karyotype

          4. Uterine diseases including large intramural myomas, severe endometriosis, severe
             adenomyosis, severe congenital uterine malformations, endometrial tuberculosis,
             vaginitis and endometritis

          5. Systemic diseases: hypertension, diabetes, and so on

          6. Contraindications to pregnancy

          7. Contraindications to hormone replacement therapy

          8. Medical history of pelvic tumors or receiving pelvic radiotherapy 9 .Involved in other
             clinical studies

        10. Unable to adhere to the follow-up
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yali Hu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Drum Tower Hospital of Nanjing University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yali Hu, MD,PhD</last_name>
    <phone>025-83106666</phone>
    <phone_ext>11201</phone_ext>
    <email>glyyhuyali@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yali Hu, MD,PhD</last_name>
      <phone>025-83106666</phone>
      <phone_ext>11201</phone_ext>
      <email>glyyhuyali@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Yali Hu</investigator_full_name>
    <investigator_title>Professor，Chief Physician of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>thin endometrium</keyword>
  <keyword>infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

